SuperworthbioAffinity Technologies EPS BIAF
Diluted earnings per share by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- −$103.50
- Latest quarter, Q2 FY26
- −$9.60
- Fiscal year 2025
- −$229.80
bioAffinity Technologies' earnings per share was −$103.50 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$9.60.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$229.80 | n/a |
| FY2024 | −$338.40 | n/a |
| FY2023 | −$400.50 | n/a |
| FY2022 | −$877.50 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$9.60 | n/a | −$103.50 | |
| Q1 FY26 | −$12.15 | n/a | −$169.95 | |
| Q4 FY25 | −$10.65 | n/a | −$229.80 | |
| Q3 FY25 | −$71.10 | n/a | −$309.45 | |
| Q2 FY25 | −$76.05 | n/a | −$310.95 | |
| Q1 FY25 | −$72.00 | n/a | −$320.40 | |
| Q4 FY24 | −$90.30 | n/a | −$338.40 | |
| Q3 FY24 | −$72.60 | n/a | −$360.60 | |
| Q2 FY24 | −$85.50 | n/a | −$405.00 | |
| Q1 FY24 | −$90.00 | n/a | −$409.50 | |
| Q4 FY23 | −$112.50 | n/a | −$400.50 | |
| Q3 FY23 | −$117.00 | n/a | −$378.00 |
Against its peers
Companies in Healthcare nearest bioAffinity Technologies' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BIAFbioAffinity Technologies | −$103.50 | |
| OXBROXBRIDGE RE HOLDINGS | $0.02 | |
| EDUCEducational Development | $0.19 | |
| GTIMGood Times Restaurants | $0.21 | +75% a year |
| Peer median | $0.19 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on bioAffinity Technologies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.